HIV treatment Biktarvy in early pregnancy
Treatments studied
Part of Infections clinical trials.
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older with HIV.
- You have been taking Biktarvy (B/F/TAF) for at least 6 months.
- Your HIV viral load has been under 50 copies/mL for 6 months and is still under 50 at screening.
- You are 12 weeks pregnant or less at the time of screening.
- You do not have an active hepatitis C infection.
- You have not had an AIDS-related infection in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This trial looks at whether screening pregnant women with HIV for tuberculosis (TB) and offering preventive treatment can improve health for both mother and baby. It may help keep you from getting active TB and protect your health during pregnancy.
This study looks at how well women with HIV stay in care while taking the medication Biktarvy (a combination of three drugs in one pill). It aims to understand their health outcomes and support better care.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.